| Symbol | EYPT |
|---|---|
| Name | EYEPOINT, INC. |
| Sector | UNDEFINED |
| Region | UNDEFINED |
| Industry | Laboratory Analytical Instruments |
| Address | 480 PLEASANT STREET, WATERTOWN, MA 02472 |
| Telephone | 617-926-5000 |
| Fax | — |
| — | |
| Website | — |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001314102 |
| Description | None |
(10% Negative) EYEPOINT, INC. (EYPT) Announces Delay in profile Trials for DURAVYU Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment
Read moreEyePoint Announces Third Consecutive Positive DSMC Recommendation for Phase 3 Wet AMD Trials for DURAVYU™, Building Confidence Ahead of Mid-2026 Topline Data
Read moreNew Form SCHEDULE 13G/A - EyePoint, Inc. <b>Filed:</b> 2026-05-13 <b>AccNo:</b> 0000919574-26-002911 <b>Size:</b> 12 KB
Read moreEyePoint Reports First Quarter 2026 Financial Results and Highlights Recent Corporate Developments
Read moreNew Form DEFA14A - EyePoint, Inc. <b>Filed:</b> 2026-04-27 <b>AccNo:</b> 0001193125-26-182077 <b>Size:</b> 898 KB
Read moreRibeiro Ramiro 🟡 adjusted position in 2.4K shares (1 derivative) of EyePoint, Inc. (EYPT) at $15.00 Transaction Date: Apr 17, 2026 | Filing ID: 000010
Read moreNew Form SCHEDULE 13G/A - EyePoint, Inc. <b>Filed:</b> 2026-03-26 <b>AccNo:</b> 0000102909-26-001250 <b>Size:</b> 7 KB
Read more